[news] direct reporting network Beijing on May 2nd (China Times (6.720, 0.02) Zhejiang Conba pharmaceutical Limited by Share Ltd, 0.30%) (hereinafter referred to as "Conba", 600572) chairman Hu Jiqiang, President of Wang Ruwei, recently issued an apology announcement, did not achieve the company in 2015 a major asset purchase target profit forecast number of explain and apologize. And this took 500 million listed companies to purchase gold and silver standard, at a price of 345 million, sale to another holding company Conba Hu Jiqiang actual controller name.

Actual loss forecast earnings

Conba in December 2014 to 270 million yuan in cash to the transferee Zhejiang Zhencheng medicine online Limited by Share Ltd (hereinafter referred to as "Zhencheng medicine") 30.81% of the shares, and in June 2015 to 233 million yuan in cash to acquire a 26.44% stake in the company. Two transactions total 500 million yuan investment holding Conba Zhencheng medicine 57.25% meter 91 million 600 thousand shares of Zhen Cheng pharmaceutical holdings.

Conba June 2015 major asset purchase report disclosure, Zhencheng medicine is a medical health e-commerce channels and value-added service providers, is one of the first to get B2B medical electronic business qualification of the enterprise, also has a medical B2B e-commerce platform.

According to the statement of listed companies Conba, is actively study and explore the reform and innovation to create a network of sales channels and marketing system. By holding Prudential medicine, through capital bonds to promote the two sides in the field of resource integration, business development and other areas to further deepen, accelerate and expand cooperation. The company can accelerate the layout of the drug into the field of electricity providers, broaden marketing channels, improve the industrial chain layout.

In view of the fact that according to the accountants as the subject of this transaction in the company issued by the Department of audit report, "[2015]0289, the major asset restructuring of listed companies management approach" article twelfth listed companies in 12 months for the purchase and sale of the same or related assets related to the proportion of the applicable securities and Futures Commission (No. eleventh legal opinions Announcement No. [2011]5), the transaction to buy the underlying asset last fiscal year (year 2014) operating income of listed companies accounted for more than 50% of the corresponding index, achieve the "restructuring management approach" article twelfth on major asset restructuring standards, therefore, the transaction constitutes a major asset restructuring Conba 2014 (a major asset buy).

Hack ie node is first script

Apology notice disclosure, Jane Cheng medicine 2016 actual performance loss of 18 million 536 thousand and 500 yuan, while the original forecast earnings of $82 million 453 thousand and 800, the difference between the one hundred million, the completion rate of -122.48%.

Companies that are affected by the policy

Jane Cheng medicine 2015 and 2016 operating results were not up to expectations, of which 2015 annual net profit of $27 million 493 thousand and 500, net profit forecast of 51.92%. This is in response to Conba are affected by various factors such as policy changes, market competition and interior modulation etc..

Conba said that since the second half of 2015, the relevant departments of the state has greatly strengthened the related fields and the application of Internet supervision. August 2016, the State Food and drug administration notified the Hebei, Shanghai, Guangdong food and drug administration, called for the end of the Internet third party platform drug online retail pilot. And, in the context of constantly strengthening drug safety supervision, the relevant departments of the state has been issued to solicit opinions online prescription drug sales policy in the short term will be difficult to formally introduced.

Meanwhile, the central government to control the flow of drugs to reduce the circulation of drugs in the pharmaceutical sales of the two vote system policy has been clearly related to the pilot and rapid advance in the province. These policies and the change of market environment, the main pharmaceutical business B2B business based on the use of electronic business platform Zhencheng medicine "medicine 5 10000", "Yunlian thousand business" network virtual mode to further expand the business to bring greater difficulties, and lead to Zhencheng medicine part of customer churn, business development is started serious adverse effects and impact.

On the other hand, because the operators in the field of B2B e-commerce into new increase, the market competition intensifies, the Zhencheng medicine original customer relationship and business impact, the original varieties of high margin sales gross margin decline, especially in the area of the new medicine business class competition through lower prices, and even some enterprises the variety of ultra low-cost promotions for the market, Zhencheng medicine stable business was forced to cut prices to deal with moderate. The above factors lead to the decline in revenue and profitability of pharmaceutical products.

In addition, the scale of the supply chain financial services business decline, the cost of capital decreased, impairment of assets impairment provision, but also on the performance of the pharmaceutical Jane has an impact.

Losing money

In December 8, 2016, Conba announcement, will hold the Zhencheng medicine all 57.25% shares transferred to the company's actual control of Hu Jiqiang under the name of another holding company Zhejiang Bookcom pharmaceutical investment Co. ltd.. The transfer was completed on December 27, 2016. The move also gives listed companies to carry out impairment of assets 43 million 610 thousand and 800 yuan.

Kangenbei secretaries Yang Junde has said that the loss of 40 million yuan is now in accordance with the benchmark price of enterprise assets on the book value calculated. "The original acquisition is to spend 500 million yuan, the annual report has provided 55 million impairment later, change the actual cost of Zhencheng medicine, has been accounted for, nuclear off, not the original purchase price does not move, according to the book on the subject matter in October 31, 2016 the cost of the transfer of the price cut, but also a loss of 40 million yuan the rest."

In fact, in the acquisition of Conba Zhencheng medicine at the beginning of June 6, 2015, Conba of Shanghai on major asset restructuring report reply, the SSE has mentioned the risk of drug sales for the new Zhencheng medicine will be the future profit compression, but that "the Conba target company risk is very small".

Now, the risk of the Shanghai Stock Exchange prompted a prophecy, in the apology announcement Conba, said: "according to the provisions of the" measures for the administration of major asset restructuring of listed companies fifty-ninth, we (Hu Jiqiang and Wang Ruwei) as a listed company chairman, President of this sincere apology to the majority of investors!

Insiders pointed out that two years ago, the concept of online medical Internet plus hot, many listed companies have to cater to the concept of speculation in high premium acquisitions, Conba Zhencheng medicine on the subject of failure and resold the equity related transactions, is equal to the listed companies and investors in the pay for the original enthusiasm.

Famous economics expert Song Qinghui said, optimistic about the subject matter from the subject matter to look bad and resold and losses of listed companies decision hasty, feasibility research, Conba do need to take part of the corresponding responsibility to investors.